benefits of glp-1 receptor agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies GLP-1 receptor agonists | How
Description
Each study was rated as low risk, some concerns, or high risk
It causes reduced appetite and the release of insulin
95% CI 0.12, 0.03) were observed with significantly reduced changes in triglycerides (Fig
2018 Apr 3;27(4):740-756
GLP-1 receptor agonists work by mimicking the incretin hormone glucagon-like peptide-1, which enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety
doi: 10.1007/s00204-021-03068-2 [DOI] [PubMed] [Google Scholar] 147.Badiani A, Belin D, Epstein D, et al
